Welcome to our dedicated page for Clearside Biomed SEC filings (Ticker: CLSD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearside Biomedical, Inc. (CLSD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, proxy materials, and other documents filed with the U.S. Securities and Exchange Commission. For a biopharmaceutical issuer focused on ophthalmology, these filings are a primary source of information on clinical programs, licensing arrangements, capital structure changes, and corporate transactions.
Clearside’s Form 8-K filings have documented several key events. One 8-K dated November 25, 2025 reports that the company filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (Case No. 25-12109). That filing explains that Clearside will operate as a debtor-in-possession and that its objective in the case is to pursue a sale of substantially all of its assets through a court-supervised process. The same 8-K also discloses a Nasdaq determination to delist CLSD, with trading on Nasdaq scheduled to be suspended and the common stock expected to trade on the over-the-counter market under the symbol CLSDQ.
Other 8-K filings describe Nasdaq listing compliance matters and corporate actions taken in response. These include notices of non-compliance with minimum bid price and market value of listed securities requirements, stockholder approval of a reverse stock split, and a one-for-fifteen reverse stock split with a corresponding reduction in authorized shares. Additional 8-Ks outline amendments to royalty monetization agreements involving Clearside Royalty LLC and entities managed by HealthCare Royalty Management, LLC, including adjustments to royalty caps, additional consideration, and changes to foreclosure rights on pledged equity.
Clearside’s proxy materials, such as the definitive proxy statement on Schedule 14A for a 2025 special meeting, provide detail on proposals like the reverse stock split and authorized share reduction, voting procedures, and ownership information. These documents help investors understand how the company’s capital structure is being managed in the context of listing requirements and strategic options.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain the practical implications of each document. For CLSD, this includes highlighting how Chapter 11 proceedings, reverse stock splits, royalty transactions, and Nasdaq listing decisions relate to the company’s SCS® injection platform, its XIPERE® commercialization agreements, and its CLS-AX and preclinical ophthalmology programs. Filings related to executive and director matters, equity plans, and other governance topics can also be consulted to build a fuller picture of Clearside’s regulatory and corporate history.
Clearside Biomedical, Inc. reported that on August 28, 2025 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Global Market’s minimum Market Value of Listed Securities requirement of $50,000,000. The notice does not immediately affect trading, and the company has until February 24, 2026 to regain compliance by maintaining an MVLS of at least $50,000,000 for 10 consecutive business days.
The company is already in the hearings process after a prior Nasdaq staff determination to delist its shares for failing to meet the $1.00 minimum bid price rule. To address this, stockholders approved a proposal at a special meeting on August 29, 2025 authorizing the board to implement a reverse stock split in a range of 1‑for‑5 to 1‑for‑15 and to proportionally reduce authorized common shares. The proposal passed with 46,485,055 votes for, 2,220,186 against, and 458,996 abstentions out of 49,164,237 shares represented.
Clearside Biomedical (CLSD) reported cash and cash equivalents of $9.4 million as of June 30, 2025 and total assets of $15.3 million, against total liabilities of $64.1 million, driven largely by a $55.7 million liability related to the sale of future royalties. The company recorded a $12.7 million net loss for the six months ended June 30, 2025 and an accumulated deficit of $368.0 million. License and other revenue for the six months was $2.8 million, including a $1.5 million milestone from Arctic Vision.
In July 2025 the company initiated a formal strategic review and retained Piper Sandler, paused internal R&D and implemented a workforce reduction, estimating third-quarter severance charges of approximately $2.6 million. Management states that, based on current plans, cash on hand is insufficient to fund operations for the next 12 months, and the company disclosed substantial doubt about its ability to continue as a going concern. The company also failed to regain Nasdaq's $1.00 minimum bid requirement and expects a delisting notice, while seeking stockholder approval for a possible reverse split.
Clearside Biomedical (CLSD) has called a 29 Aug 2025 Special Meeting to vote on one item: authorising its Board, within the next 12 months, to implement a reverse stock split at any ratio from 1-for-5 to 1-for-15 and to cut authorised common shares proportionally. The move is designed to lift the share price above Nasdaq’s $1.00 bid-price minimum after CLSD received a non-compliance notice on 7 Feb 2025; delisting could occur after 6 Aug 2025 if the price is not restored. A split would shrink the 78.5 M shares outstanding to 15.7 M–5.2 M and trim authorised shares from 400 M to 80 M–26.7 M. Fractional interests will be cashed out. Brokers may vote uninstructed street-name shares because the proposal is deemed “routine,” so only a simple majority of votes cast is required. Ownership percentages, rights and par value ($0.001) remain unchanged, while equity plan reserves and option exercise prices adjust mechanically. The Board can abandon the action if market conditions improve. Management warns that liquidity might fall, odd lots may form and the post-split price is not guaranteed, but believes maintaining the Nasdaq listing and investor visibility outweigh those risks. Record date: 28 Jul 2025.